Tonix Pharmaceuticals Awarded Up To $34M OTA By U.S. Defense Threat Reduction Agency To Develop Broad-Spectrum Antiviral Agents; Focus On TNX-4200 Program For Military Medical Readiness In Biological Threat Environments; Supports Preclinical Evaluation And Phase 1 Clinical Study
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has been awarded up to $34 million by the U.S. Defense Threat Reduction Agency to develop broad-spectrum antiviral agents, focusing on the TNX-4200 program. This funding will support preclinical evaluation and a Phase 1 clinical study aimed at enhancing military medical readiness in biological threat environments.
July 29, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has received up to $34 million from the U.S. Defense Threat Reduction Agency to develop the TNX-4200 antiviral program. This funding will support preclinical and Phase 1 clinical studies, potentially enhancing the company's revenue and market position.
The significant funding from a government agency for the development of a key antiviral program is likely to boost Tonix Pharmaceuticals' stock. The support for preclinical and Phase 1 studies indicates strong potential for future revenue and market position enhancement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100